Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: sumatriptan Clear all
Completed Phase 1 Interventional

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

NCT00723983
View directory record Official record
Conditions
Migraine Disorders
Interventions
Sumatriptan succinate, NP101 Study Patch
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea

NCT00329459
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
34
States / cities
Mesa, Arizona • Little Rock, Arkansas • Fair Oaks, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

NCT01016834
View directory record Official record
Conditions
Migraine
Interventions
Sumavel DosePro, Sumatriptan
Device · Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 4, 2026, 2:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy of Sumatriptan With Naprosyn in Migraine With Aura

NCT00893594
View directory record Official record
Conditions
Migraine With Aura
Interventions
sumatriptan with naprosyn, placebo
Drug
Lead sponsor
Dent Neurologic Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers

NCT00720018
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101 Sumatriptan Iontophoretic Transdermal Patch
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System

NCT00614029
View directory record Official record
Conditions
Pharmacokinetics, Bioequivalence
Interventions
Sumatriptan (via Intraject System)
Device
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Treximet in the Treatment of Chronic Migraine

NCT01090050
View directory record Official record
Conditions
Chronic Migraine
Interventions
Sumatriptan/Naproxen Sodium, Naproxen Sodium
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Springfield, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine

NCT01300546
View directory record Official record
Conditions
Migraine
Interventions
Sumatriptan/Naproxen Sodium, Naproxen Sodium
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Newport Beach, California • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack

NCT00530517
View directory record Official record
Conditions
Migraine Headache
Interventions
Intraject Sumatriptan
Device
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Chicago, Illinois • Springfield, Missouri • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

NCT01430442
View directory record Official record
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

NCT00792636
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
49
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine

NCT00385008
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches

NCT00433732
View directory record Official record
Conditions
Migraine Headaches
Interventions
sumatriptan, naproxen sodium
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2007 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches

NCT00434083
View directory record Official record
Conditions
Migraine Headaches
Interventions
sumatriptan, naproxen sodium
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 11, 2007 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.

NCT00989625
View directory record Official record
Conditions
Migraine Disorders
Interventions
This is a pharmacokinetic study (Treximet)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Wichita, Kansas • Louisville, Kentucky • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240630
View directory record Official record
Conditions
Migraine Disorders, Migraine
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
50
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

NCT01381796
View directory record Official record
Conditions
Compare Bioequivalence Patches Previously Used in the NP101-007 Study
Interventions
NP101, sumatriptan succinate
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

NCT00806546
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

Ictal and Interictal Inflammatory Markers in Migraine

NCT01138150
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

NCT03076970
View directory record Official record
Conditions
Migraine
Interventions
lasmiditan 200 mg, Sumatriptan, matching placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2019 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults

NCT00573170
View directory record Official record
Conditions
Migraine Disorders, Migraine, Acute
Interventions
TREXIMET®, Butalbital-containing Combination Medications (BCM), placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
107
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2010 · Synced Sep 4, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

NCT01329562
View directory record Official record
Conditions
Menstrual Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Springfield, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 4, 2026, 2:56 AM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 4, 2026, 2:56 AM EDT
Completed No phase listed Observational

Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women

NCT05854992
View directory record Official record
Conditions
Migraine, Cardiovascular Diseases, Pregnancy
Interventions
Acute migraine treatment with any prescribed triptans, Standard of care management of acute migraine without triptans
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
68,419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 4, 2026, 2:56 AM EDT